Spear Bio

Spear Bio

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://www.spear.bio

Last Round

Series A

Jul 29, 2024

Total Funding Raised

$45M

Momentum Score

50 /100

Company Overview

Spear Bio is a biotechnology company specializing in ultrasensitive protein detection technology that enhances self-testing and telemedicine diagnostics by enabling the quantification of minute protein biomarkers from at-home samples for improved clinical workflows.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

ultrasensitive immunoassayimmunoassay kitsbiomarker detectionliquid biopsySPEAR technologyproteomicsmicrosamplingneurodegenerative disease researchAlzheimer's biomarkersqPCR analysisELISA alternativesample testing servicewash-free immunoassaylow-abundance biomarkersneutralizing antibody testlife science toolsSuccessive Proximity Extension Amplification Reaction

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spear Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Spear Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AJul 29, 2024
SeedNov 29, 2023

Key People

Founding team and executive leadership

Feng Xuan

Co-Founder CEO

Founding Team

Zidong Wang

Chief Operating Officer

Executive Team

Spear Bio Investors

Notable investors and investment history

InvestorRounds
CDH InvestmentsSeries A, Seed
Maverick VenturesSeed, Series A
Yonjin CapitalSeries A
Yonghua CapitalSeed
Foresite CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2026

    Presented at AD/PD 2026 and launched new neurodegenerative assays.

  • Apr 9, 2026

    Launched new ultra-sensitive neurodegenerative assays at AD/PD 2026.

Spear Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Spear Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Spear Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range49
Year Founded2021
Last FundingJul 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.